logo

Repros Therapeutics Inc. (RPRX)



Trade RPRX now with
  Date
  Headline
2/2/2017 9:23:16 AM Repros Therapeutics President And CEO Joseph Podolski Is Leaving; Larry Dillaha Named President And CEO On Interim Basis
1/30/2017 9:17:30 AM Repros: FDA Grants End Of Phase 2 Meeting On Phase 3 Requirements For Oral Proellex In Treatment Of Uterine Fibroids
12/6/2016 8:04:24 PM Repros : FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism
11/8/2016 4:06:08 PM Repros Therapeutics Q3 Loss/share $0.17 Vs. Loss $0.27 Year Ago
10/5/2016 10:39:00 AM Repros Reports Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
9/26/2016 9:23:20 AM FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
8/9/2016 9:17:36 AM Repros Therapeutics Q2 Loss $4.3 Mln Or $0.18/shr Vs. Loss $7.8 Mln Or $0.32/shr Prior Year
5/16/2016 4:04:58 PM Repros Appoints Patrick Fourteau As Chairman Of The Board
5/10/2016 9:18:00 AM Repros Therapeutics Q1 Net Loss $4.8 Mln Or $0.20/shr Vs. Net Loss Of $8.5 Mln Or $0.35/shr Prior Year
3/14/2016 9:17:39 AM Repros Therapeutics Q4 Net Loss $6.3 Ml Or $0.26/shr Vs Net Loss Of $7.4 Mln Or $0.31/shr Last Year
1/11/2016 9:18:54 AM Repros Says Court Of Appeals’ Affirmed Summary Judgment In Favor Of Company
12/1/2015 9:55:43 AM Repros Therapeutics Gets Complete Response Letter From FDA For Enclomiphene
11/9/2015 9:20:52 AM Repros Therapeutics Q3 Net Loss $6.6 Mln Or $0.27/shr Vs. Net Loss Of $7.6 Mln Or $0.32/shr Last Year